Login to Your Account

Sage postpartum depression win delivers optimism and growth spurt for shares

By Randy Osborne
Staff Writer

Tuesday, July 12, 2016

Calling Sage Therapeutics Inc.'s drug candidate for PPD "completely unlike anything we see in psychiatry currently," principal investigator Samantha Meltzer-Brody said that the resoundingly successful phase II trial with SAGE-547 showed safety and efficacy that researchers need to investigate further but offers great hope for patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription